Request Complimentary Product Samples
MAXALT^® (rizatriptan benzoate) Tablets
MAXALT-MLT^® (rizatriptan benzoate) Orally Disintegrating Tablets

 Patient Product Information

Registered and validated MDs/DOs may print out a form to request complimentary samples of Merck products.

To request complimentary samples, you must sign in. You will then be shown a list of the different complimentary sample formulations for that product that you may request. When you finalize your requests, you will need to print out a Sample Request Form. This form must then be signed, dated, and returned to Merck via fax or mail using the fax number or address specified on the form. You should receive the samples requested via UPS delivery within 14 business days of Merck receiving the completed form.

Viewing files designated with requires a PDF reader

MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. MAXALT should not be given to patients with ischemic heart disease (eg, angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease. Because MAXALT may increase blood pressure, it should not be given to patients with uncontrolled hypertension. MAXALT should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide. MAXALT should not be administered to patients with hemiplegic or basilar migraine. Concurrent administration of MAO inhibitors or use of rizatriptan within 2 weeks of discontinuation of MAO inhibitor therapy is contraindicated. MAXALT is contraindicated in patients who are hypersensitive to rizatriptan or any of its inactive ingredients. Because of the potential of this class of compounds (5-HT1B/1D agonists) to cause coronary vasospasm, MAXALT should not be given to patients with documented ischemic or vasospastic coronary artery disease. The most common adverse events include asthenia/fatigue, somnolence, pain/pressure sensations, and dizziness, and they appear to be dose related. Potentially important adverse events that have occurred in clinical practice and reported through postmarketing surveillance include cardiovascular: myocardial ischemia, myocardial infarction; cerebrovascular: stroke; special senses: dysgeusia; general: hypersensitivity: angioedema (eg, facial edema, tongue swelling, pharyngeal edema), wheezing, toxic epidermal necrolysis. Serious adverse cardiac events, including acute myocardial infarction, have been reported within a few hours following the administration of rizatriptan. Life-threatening disturbances of cardiac rhythm and death have been reported within a few hours following the administration of other 5-HT1 agonists. Considering the extent of use of 5-HT1 agonists in patients with migraine, the incidence of these events is extremely low. MAXALT can cause coronary vasospasm.